Glimsay M 3 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 3 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, enhancing glucose uptake in muscle tissues. The dual mechanism of action addresses both insulin deficiency and insulin resistance, providing effective glycemic control. Glimsay M 3 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan including diet and exercise. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and rarely hypoglycemia due to glimepiride. Regular monitoring of blood glucose levels, renal function, and periodic assessment of liver enzymes is recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability. This combination therapy offers a convenient and effective option for patients inadequately controlled on monotherapy.

Dosage & How to Use